Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
Trackers Drugs Comparisons API
Trackers› Clinical trials› Cork
Clinical trial register · Ireland

Clinical Trials in Cork, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Ireland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Alert me on this filter Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 602 matching records held by the registry are in this view. Synced 06 Oct 2026, 03:15 UTC
602
Studies in scope
all four open statuses
306
Recruiting now
open to new participants
169
Lead sponsors
across recruiting studies
37
Irish site locations
across all listed studies
Phase mix of the 306 recruiting studies
Phase 3 94 Not applicable 74 Observational 72 Phase 2 26 Phase 1/2 21 Other 19
Narrow the register Reset
Matches title, registry number, sponsor, intervention and condition.
Recruitment status
Phase
Lead sponsor
University College Cork 17 Merck Sharp & Dohme LLC 15 Cancer Trials Ireland 8 AstraZeneca 7 AbbVie 7
Site location
Dublin 483 Cork 170 Galway 125 Limerick 56 Waterford 52
All 37 locations
Target enrolment
to

Trials with a site in Cork

170 of 602 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Irish sites
Start
Not yet open
Patient-Initiated Follow-Up for Women After Early Breast Cancer Treatment (LYSA2PIFU)
NCT07840534 Breast Cancer, Breast Cancer Survivorship, Cancer Survivorship, Endocrine Therapy
University College Cork
Not applicable
30
Cork
2026-10-01
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161 Myelofibrosis, Anemia
DrugElritercept
Takeda
Phase 3
324
Cork, Dublin, Galway
2026-09-10
Not yet open
Newborn Brain Assessment - CergenX Wave
NCT07857070 Neonatal Encephalopathy, Neonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy), Neonatal Encephalopathy, Unspecified
CergenX Limited
Observational
165
Cork
2026-09
Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680 Solid Tumors
DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab
Bristol-Myers Squibb
Phase 2
260
Cork, Dublin
2026-07-27
Recruiting
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
NCT07106632 Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer
UNICANCER
Phase 3
3,380
Cork, Dublin, Limerick, Tullamore, Waterford
2026-06-26
Active, closed
Safety and User Experience of BP-CBB
NCT07628608 Safety and Tolerability in Healthy Volunteers
Bactolife A/S
Not applicable
60
Cork
2026-06-16
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT07422480 Myelodysplastic Syndrome, Anemia
DrugsElritercept·Epoetin Alfa
Takeda
Phase 3
300
Cork, Dublin, Galway
2026-05-21
Recruiting
INSPIRE: INnovative SABR for Prostate Cancer All IREland
NCT07552168 Prostate Adenocarcinoma
Cancer Trials Ireland
Phase 2
136
Dublin, Cork, Waterford
2026-04-23
Recruiting
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
NCT07546500 Ovarian Cancer
DrugAzenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Cork, Dublin
2026-04-17
Recruiting
Generating Intervals of Reference FFor Early Life Brain Biomarkers.
NCT07585149 Reference Intervals, Biomarker in Early Diagnosis, Neonatal
University College Cork
Observational
150
Cork
2026-04-13
Not yet open
An Intervention Study in Healthy Infants Aged 0-6 Months With Probiotics Lacticaseibacillus Rhamnosus LRa05 (LRa05) and Bifidobacterium Animalis Subsp. Lactis BLa80 (BLa80) vs. Placebo, for Promoting Gut Microbiome Development.
NCT07505329 Less Than 3 Months Old, Healthy Infants
University College Cork
Not applicable
300
Cork
2026-04
Recruiting
CP: Intestinal Permeability
NCT07586930 Intestinal Permability
Rousselot BVBA
Not applicable
92
Cork
2026-03-25
Recruiting
The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals With Excessive Body Weight
NCT07453823 Gastrointestinal Microbiome (Focus), Gastrointestinal Symptoms
Chr Hansen - part of Novonesis
Not applicable
90
Cork
2026-03-18
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497 Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Cork, Dublin
2026-03-16
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558 Ovarian Neoplasms, Ovarian Cancer
DrugsMvasi·Sacituzumab tirumotecan·Avastin·Bevacizumab
Merck Sharp & Dohme LLC
Phase 3
900
Cork, Dublin
2026-02-16
Not yet open
Improving ADHD Symptoms and Quality of Life Through Diet
NCT07376746 ADHD
University College Cork
Not applicable
200
Cork
2026-02
Recruiting
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091 Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring
Phase 2
84
Cork, Dublin
2026-01-22
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703 Cervical Cancer
DrugsMvasi·Sacituzumab tirumotecan·Paraplatin·Avastin
Merck Sharp & Dohme LLC
Phase 3
1,023
Cork, Dublin
2026-01-19
Recruiting
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
NCT06931717 Non-Small Cell Lung Cancer
DrugCemiplimab
ETOP IBCSG Partners Foundation
Phase 3
390
Cork, Dublin
2026-01-12
Recruiting
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
NCT07140172 Breast Cancer
University Hospital, Basel, Switzerland
Not applicable
1,060
Cork, Dublin, Galway
2026-01-01
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809 Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin
AstraZeneca
Phase 3
1,100
Cork, Dublin, Waterford
2025-12-29
Recruiting
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562 Multiple Myeloma
DrugsLinvoseltamab·Daratumumab·Lenalidomide·Dexamethasone
European Myeloma Network B.V.
Phase 3
1,000
Cork, Dublin, Limerick
2025-12-23
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336 Breast Neoplasms, Neoplasm Metastasis
DrugsTersolisib·Exemestane·Anastrozole·Abemaciclib
Eli Lilly and Company
Phase 3
800
Cork, Dublin, Galway
2025-12-22
Recruiting
The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults
NCT07231783 Healthy Aging, Muscle Function
Amazentis SA
Not applicable
120
Cork
2025-12-10
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402 Renal Cell Carcinoma
DrugsZanzalintinib·Belzutifan·Cabozantinib
Merck Sharp & Dohme LLC
Phase 3
904
Cork, Dublin
2025-11-26
Recruiting
Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM)
NCT07425002 Breast Cancer
Cancer Trials Ireland
Not applicable
1,600
Dublin, Cork, Galway
2025-11-11
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517 Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin
Boehringer Ingelheim
Phase 3
670
Cork
2025-11-07
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804 Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan
Eli Lilly and Company
Phase 3
1,630
Cork, Dublin
2025-10-22
Recruiting
The Effect of α-GPC on Cognitive Function and Sports Performance
NCT07267845 Healthy Participants
Nanjing Nutrabuilding Bio-tech Co., Ltd.
Not applicable
80
Cork
2025-10-21
Recruiting
Prediction of Venous Thrombosis During chemotherapy-the PINPOINT Study
NCT07196020 Venous Thromboembolism, Cancer
University of Dublin, Trinity College
Observational
380
Cork, Dublin
2025-10-01
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762 Urothelial Cancer
DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
470
Cork, Dublin
2025-09-30
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275 Primary Membranous Nephropathy
DrugsPovetacicept·Tacrolimus
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Cork, Dublin, Galway
2025-09-30
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
NCT06959524 Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Boston Scientific Corporation
Not applicable
1,616
Cork, Dublin, Galway
2025-08-21
Recruiting
The Satiety Control Optimization by Nutritional Enhancement Study
NCT07420023 Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease
University College Cork
Not applicable
24
Cork
2025-08-18
Recruiting
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
NCT07075016 Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
227
Cork, Dublin, Galway
2025-08-05
Recruiting
Sleep Promoting Properties of a Botanical Extract in a Population Complaining From Non-Restorative Sleep (NRS)
NCT07085819 Non Restorative Sleep, Sleep Disorder (Disorder)
Kerry Group P.L.C
Not applicable
160
Cork
2025-07-15
Active, closed
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
NCT07003919 Allergy, Peanut Allergy
DBV Technologies
Phase 3
480
Cork, Dublin
2025-06-24
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095 Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
981
Dublin, Cork, Drogheda, Galway, Mullingar
2025-06-20
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892 Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 3
1,755
Cork, Dublin
2025-06-09
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504 Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,123
Dublin, Cork
2025-05-22
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737 Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Dublin, Cork
2025-05-13
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285 Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
Cork, Dublin, Limerick
2025-05-06
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784 NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Cork, Dublin, Galway
2025-05-06
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438 Acute Myeloid Leukemia, Adult
DrugRevumenib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
448
Cork, Dublin, Galway, Waterford
2025-05-05
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310 Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin
Mirati Therapeutics Inc.
Phase 3
630
Cork, Dublin
2025-04-24
Recruiting
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
NCT05784428 Oligometastatic Disease, Oligoprogression, Toxicity Due to Radiotherapy, Quality of Life
Robert Olson
Not applicable
598
Galway, Dublin, Cork, Waterford
2025-04-16
Recruiting
EXtubation Related Complications - the EXTUBE Study (EXTUBE)
NCT06442930 Extubation
University Health Network, Toronto
Observational
3,000
Castlebar, Cork, Dublin, Galway, Waterford
2025-04-14
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277 Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
830
Cork, Dublin, Galway
2025-04-10
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289 Eosinophilic Asthma
AstraZeneca
Phase 3
400
Ballinasloe, Cork, Dublin, Moneymore
2025-03-28
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265 Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsEfti·Pemetrexed·Keytruda·Paclitaxel
Immutep S.A.S.
Phase 3
756
Cork, Dublin
2025-03-21
Recruiting
Assessing Intellectual and Motor Outcomes in High-risk Infants
NCT06857539 Cerebral Palsy, Cerebral Palsy (CP), Cerebral Palsy Children, High-risk Infants
University College Cork
Observational
600
Cork, Dublin
2025-03-21
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485 Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Celgene
Phase 3
960
Cork, Dublin
2025-03-13
Recruiting
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
NCT06764693 Psoriatic Arthritis
AbbVie
Observational
1,200
Dublin, Elm Park, Tralee, Cork
2025-01-31
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990 Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Cork, Dublin
2025-01-28
Active, closed
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455 Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
NRG Oncology
Phase 3
274
Dublin, Galway, Cork
2024-12-12
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824 PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsDocetaxel·Pembrolizumab
Genmab
Phase 3
191
Cork, Dublin, Limerick, Waterford
2024-11-25
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884 Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Dublin, Cork
2024-11-15
Recruiting
AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis
NCT06709209 Ulcerative Colitis (UC)
University College Cork
Observational
300
Cork
2024-11-04
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422 Carcinoma, Non-Small-Cell Lung
DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
680
Cork, Dublin
2024-10-21
Recruiting
Microbiome Immunotherapy Neoadjuvant Assessment
NCT06709651 Triple Negative Breast Cancer
University College Cork
Observational
30
Cork
2024-10-02
Active, closed
Safety and Tolerance of a Novel Three-Strain Probiotic in Healthy Adults
NCT07566884 Healthy Adults
Pendulum Therapeutics
Not applicable
30
Cork
2024-09-23
Recruiting
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524 Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
DrugLinvoseltamab
Regeneron Pharmaceuticals
Phase 2
116
Galway, Cork, Dublin
2024-09-16
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142 Immunoglobulin A Nephropathy
DrugPovetacicept
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Cork, Dublin, Galway, Waterford
2024-08-30
Recruiting
Investigating Mechanistic Predictors of Interpatient Variability and Temozolomide (TMZ) Induced Haematological Toxicity for Glioma Patients
NCT06546631 Glioma
University College Cork
Observational
55
Cork
2024-08-22
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180 Cervical Cancer
DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
686
Cork, Dublin
2024-07-24
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228 Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 3
1,400
Drogheda, Cork, Dublin
2024-06-27
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374 Triple-Negative Breast Cancer
DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,530
Cork, Dublin, Galway
2024-06-24
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682 Atopic Dermatitis
DrugTralokinumab
LEO Pharma
Phase 3
195
Cork, Crumlin
2024-06-10
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386 Prostatic Neoplasms, Castration-Resistant
DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere
Merck Sharp & Dohme LLC
Phase 1/2
220
Dublin, Cork
2024-05-20
Recruiting
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
NCT06729671 Psychosis
University College Cork
Not applicable
70
Cork
2024-05-16
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820 Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Cork, Dublin
2024-04-18
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176 Breast Neoplasms
DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
1,200
Cork, Dublin
2024-04-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064 Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
Dublin, Cork, Galway
2024-04-10
Recruiting
PENG Block: Continuous Infusion vs. Programmed Intermittent Bolus in Neck of Femur Fracture
NCT07046052 Hip Fracture, Analgesia Post Fracture
University College Cork
Not applicable
150
Cork
2024-03-28
Recruiting
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
NCT06093672 Polycythemia Vera
DrugHydroxyurea
Italfarmaco
Phase 3
220
Cork, Dublin
2024-03-26
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871 HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc
Phase 1
383
Dublin, Cork
2024-03-25
By invitation
School-aged Outcomes Post Hypoxic Ischaemic Encephalopathy
NCT07770035 Hypoxic-Ischemic Encephalopathy
University College Cork
Observational
196
Cork
2024-03-09
Recruiting
The Effects of Exercise on Gut Bacteria, Mood and Cognition in Depression
NCT06398496 Depressive Disorder, Major
University College Cork
Not applicable
40
Cork
2024-02-14
Active, closed
Assessment of Diastolic Function During the Transitional Period and Infancy Using Serial Echocardiography
NCT06200519 Diastolic Dysfunction, Neonatal Encephalopathy, Small for Gestational Age at Delivery, Transient Tachypnea of the Newborn
University College Cork
Observational
216
Cork
2024-02-12
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945 Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
250
Cork, Dublin, Galway
2023-12-30
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06285318 Relapsed/Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.
Observational
900
Cork, Dublin, Galway
2023-12-18
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958 Endometrial Cancer
DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol
Merck Sharp & Dohme LLC
Phase 3
710
Cork, Dublin
2023-12-06
Active, closed
U011 - Wireless Ultra Long-Term EEG Recordings in Epilepsy
NCT05915988 Epilepsy
UNEEG Medical A/S
Not applicable
19
Cork, Dublin
2023-12-04
Recruiting
Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases
NCT06078813 Solid Tumor Spine Metastases
Cancer Trials Ireland
Phase 1/2
126
Cork, Dublin
2023-11-21
Not yet open
Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial
NCT06115629 Esophageal Cancer, Gastric Cancer
University of Dublin, Trinity College
Phase 3
952
Cork, Dublin, Galway
2023-11
Active, closed
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
NCT05710666 HER2-positive Breast Cancer
DrugTrastuzumab deruxtecan
Cancer Trials Ireland
Phase 2
11
Galway, Dublin, Cork, Limerick
2023-10-26
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557 Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Cork, Dublin, Galway, Waterford
2023-10-05
Recruiting
Discontinuation Study
NCT05866757 Multiple Myeloma, Cancer, Hematologic Cancer
University College Cork
Not applicable
70
Cork
2023-08-28
Recruiting
Early Detection & Intervention of Cerebral Palsy in Ireland
NCT05907837 Cerebral Palsy, Neurodevelopmental Disorders
University College Cork
Observational
1,500
Cork, Dublin, Limerick
2023-07-01
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182 Hidradenitis Suppurativa
DrugUpadacitinib
AbbVie
Phase 3
1,328
Dublin, Cork, Galway, Waterford
2023-06-21
Active, closed
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
NCT05817942 Ulcerative Colitis
DrugFilgotinib
Alfasigma S.p.A.
Observational
509
Cork, Dublin
2023-06-12
Active, closed
Linking In With Advice and Supports for Men Impacted by Metastatic Cancer
NCT05946993 Survivorship, Prostate Cancer, Kidney Cancer, Urothelial Tract/Bladder Cancer, Nos
University College Cork
Not applicable
72
Cork
2023-05-08
Active, closed
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
NCT05876754 Cholangiocarcinoma
DrugIvosidenib
Servier Affaires Médicales
Phase 3
299
Cork, Dublin
2023-05-03
Active, closed
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973 Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
Terumo Europe N.V.
Observational
3,000
Cork, Dublin, Galway
2023-04-25
Active, closed
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931 Endometrial Cancer
DrugSelinexor
Karyopharm Therapeutics Inc
Phase 3
257
Dublin, Cork, Galway, Waterford
2023-04-18
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778 Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab
AbbVie
Phase 3
520
Dublin, Cork, Galway, Sligo, Waterford
2023-03-15
Active, closed
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476 Allergy, Peanut
DBV Technologies
Phase 3
600
Cork, Dublin
2023-02-21
Recruiting
Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis
NCT05347238 Late-Onset Neonatal Sepsis, Extreme Prematurity, Neonatal Hypotension
DrugsDopamine·Norepinephrine
Mount Sinai Hospital, Canada
Observational
550
Cork, Dublin
2023-02-06
Active, closed
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291 Melanoma
DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab
Regeneron Pharmaceuticals
Phase 3
1,564
Galway, Cork, Dublin
2023-01-16
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677 Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
516
Manorhamilton, Cork, Dublin
2023-01-12
Active, closed
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
NCT05429268 Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
DrugsTafasitamab·Lenalidomide
Incyte Corporation
Phase 3
82
Cork, Dublin, Galway
2022-12-23
Active, closed
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257 Cystic Fibrosis
DrugVNZ/TEZ/D-IVA
Vertex Pharmaceuticals Incorporated
Phase 3
822
Cork, Dublin, Limerick
2022-11-08
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651 Colorectal Neoplasms
DrugsTucatinib·Erbitux·Herceptin·Avastin
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Cork, Dublin, Waterford
2022-10-24
Active, closed
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05587296 Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer
Phase 3
474
Galway, Dublin, Cork, Waterford
2022-10-14
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054 Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Cork, Dublin, Galway, Sligo, Waterford
2022-10-04
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085 Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib
Celgene
Phase 3
810
Galway, Cork, Dublin, Limerick
2022-09-20
Recruiting
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
NCT05377047 Breast Cancer Stage IV, Oligometastatic Disease
Vastra Gotaland Region
Phase 3
345
Cork, Dublin, Galway
2022-09-19
Active, closed
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692 Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsCeralasertib·Durvalumab·Docetaxel
AstraZeneca
Phase 3
594
Cork, Dublin, Limerick
2022-09-15
Recruiting
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
NCT05613023 Prostate Cancer
Institute of Cancer Research, United Kingdom
Phase 3
1,128
Cork, Dublin, Limerick
2022-09-09
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797 Multiple Myeloma
DrugsTeclistamab·Lenalidomide
European Myeloma Network B.V.
Phase 3
1,594
Cork, Dublin, Galway, Limerick
2022-09-08
Active, closed
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325 SGA, Turner Syndrome, Noonan Syndrome, ISS
DrugsNorditropin·Somapacitan
Novo Nordisk A/S
Phase 3
412
Cork, Dublin
2022-08-10
Active, closed
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672 Melanoma
DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab
Regeneron Pharmaceuticals
Phase 3
1,546
Galway, Cork, Dublin
2022-07-14
Recruiting
Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying Time in Infants With Colic
NCT05512234 Colic, Infantile
BioGaia AB
Not applicable
102
Cork
2022-07-13
Active, closed
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
NCT05186753 SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis
DrugBezuclastinib
Cogent Biosciences, Inc.
Phase 2
237
Cork, Dublin
2022-06-27
Active, closed
30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants
NCT03825835 Premature Infant, Respiratory Distress Syndrome in Premature Infant, Neurodevelopmental Outcome
University of Alberta
Not applicable
1,203
Cork
2022-06-27
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997 Multiple Myeloma
DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone
Celgene
Phase 3
939
Cork, Dublin, Galway
2022-06-23
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728 Carcinoma, Renal Cell
DrugsBelzutifan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,800
Dublin, Cork
2022-03-15
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987 Endometrial Neoplasms
DrugsTaxotere·Paraplatin·Taxol·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
280
Cork, Dublin
2022-02-03
Active, closed
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
NCT04905069 Prostate Cancer
Boston Scientific Corporation
Not applicable
500
Cork
2021-12-21
Active, closed
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287 Asthma
DrugDupilumab
Sanofi
Phase 4
1,339
Cork, Dublin
2021-12-16
Active, closed
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
NCT04667663 Multiple Myeloma
DrugsPomalidomide·Daratumumab·Dexamethasone·Cyclophosphamide
Cancer Trials Ireland
Phase 1
16
Cork, Dublin, Galway
2021-12-08
Recruiting
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT04910685 Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2/3
534
Cork
2021-11-30
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996 Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Cork, Dublin, Galway, Limerick, Waterford
2021-08-27
Active, closed
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
NCT04739761 Breast Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 3
506
Cork, Dublin
2021-06-22
Active, closed
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934 Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel
Daiichi Sankyo
Phase 3
490
Cork, Dublin
2021-05-21
Active, closed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344 Muscle-invasive Bladder Cancer
DrugsTecentriq·Atezolizumab
Hoffmann-La Roche
Phase 3
761
Cork, Dublin
2021-05-03
Active, closed
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318 Chronic Lymphoid Leukemia
DrugsVenclyxto·Ibrutinib·Obinutuzumab·Venetoclax
German CLL Study Group
Phase 3
897
Cork, Dublin, Galway, Limerick, Waterford
2021-03-01
Active, closed
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414 Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
313
Cork, Dublin
2021-02-25
Recruiting
iCorMicA - Stratified Medicine in Angina
NCT04674449 Microvascular Angina, Angina, Stable, Ischemia With No Obstructive Coronary Arteries (INOCA), Coronary Microvascular Dysfunction (CMD)
NHS Greater Glasgow and Clyde
Not applicable
1,500
Cork, Dublin
2020-12-30
Active, closed
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497 IgG4 Related Disease
DrugInebilizumab
Amgen
Phase 3
135
Cork
2020-12-04
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319 HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
DrugsAdo-trastuzumab emtansine·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 3
1,600
Dublin, Cork, Limerick
2020-12-04
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596 Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Cork, Dublin, Galway, Limerick, Waterford
2020-12-02
Recruiting
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
NCT04588311 Trauma, Traumatic Injury, Traumatic Brain Injury, Wounds and Injuries
DrugEpoetin Alfa
Australian and New Zealand Intensive Care Research Centre
Phase 3
2,500
Beaumont, Cork, Dublin
2020-11-09
Active, closed
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565 HER2-negative Breast Cancer, Triple Negative Breast Cancer
DrugsXeloda·Sacituzumab Govitecan·Paraplatin·Capecitabine
GBG Forschungs GmbH
Phase 3
1,332
Cork, Dublin, Limerick, Waterford
2020-10-28
Active, closed
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
NCT04316117 Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
ECOG-ACRIN Cancer Research Group
Phase 2
138
Cork
2020-09-15
Active, closed
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
NCT04136353 Prostate Cancer
DrugDarolutamide
University of Sydney
Phase 3
1,100
Rathgar, Cork, Dublin, Galway
2020-03-31
Recruiting
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
NCT04294927 BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation
University Medical Center Nijmegen
Not applicable
3,000
Cork
2020-03-01
Active, closed
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
NCT04027309 Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
DrugsMidostaurin·Gilteritinib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
777
Cork, Dublin, Galway, Limerick
2019-12-20
Recruiting
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883 Cutaneous Melanoma, Stage II
Melanoma and Skin Cancer Trials Limited
Not applicable
2,998
Cork, Dublin
2019-12-17
Active, closed
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer
NCT03862911 Metastatic Tumors
British Columbia Cancer Agency
Not applicable
330
Rathgar, Dublin, Cork
2019-11-01
Active, closed
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364 Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8
DrugsParaplatin·Taxol·Letrozole·Paclitaxel
NRG Oncology
Phase 3
450
Cork, Dublin
2019-09-20
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297 Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
DrugsBendamustine·Zanubrutinib·Rituximab
BeOne Medicines
Phase 3
510
Cork, Dublin, Galway, Limerick, Waterford
2019-08-20
Active, closed
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
NCT03969004 Cutaneous Squamous Cell Carcinoma
DrugCemiplimab
Regeneron Pharmaceuticals
Phase 3
415
Dublin, Cork, Galway
2019-06-04
Active, closed
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263 Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
OHB Neonatology Ltd.
Phase 2
295
Cork
2019-05-09
Active, closed
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
NCT03869892 Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Capecitabine
Institut de Recherches Internationales Servier
Phase 3
856
Cork, Dublin
2019-03-21
Active, closed
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771 Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
DrugsEnasidenib·Ivosidenib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
968
Cork, Dublin, Galway
2019-03-01
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059 Breast Cancer
DrugsEpirubicin·Adriamycin·Cytoxan·Taxol
Merck Sharp & Dohme LLC
Phase 3
1,240
Cork, Dublin
2018-12-27
Active, closed
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
NCT03742895 Advanced Solid Neoplasms
DrugOlaparib
Merck Sharp & Dohme LLC
Phase 2
329
Dublin, Cork
2018-12-12
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318 Atopic Dermatitis
DrugUpadacitinib
AbbVie
Phase 3
1,533
Dublin, Cork, Waterford
2018-08-09
Active, closed
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
NCT03523858 Progressive Multiple Sclerosis (PMS)
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
927
Cork, Dublin
2018-05-28
Active, closed
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246 Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
DrugsRucaparib·Opdivo·Nivolumab
pharmaand GmbH
Phase 3
1,097
Cork, Limerick, Waterford
2018-05-14
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823 Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
747
Cork
2018-03-21
Active, closed
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03330847 Metastatic Triple Negative Breast Cancer
DrugCeralasertib
AstraZeneca
Phase 2
273
Cork, Dublin
2018-03-07
Active, closed
ATTUNE® Revision- Complex Primary in Total Knee Arthroplasty Population
NCT03153449 Primary Knee Arthroplasty
DePuy Orthopaedics
Not applicable
400
Cork
2017-09-19
Active, closed
ATTUNE Revision System in the Revision Total Knee Arthroplasty Population
NCT03153475 Revision Total Knee Arthroplasty
DePuy Orthopaedics
Not applicable
400
Cork
2017-05-30
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068 Ulcerative Colitis (UC)
DrugUpadacitinib
AbbVie
Phase 3
950
Dublin, Elm Park, Cork, Galway
2017-01-31
Active, closed
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861 Renal Cell Carcinoma
DrugsSunitinib·Everolimus·Lenvatinib·Pembrolizumab
Eisai Inc.
Phase 3
1,069
Cork, Dublin, Galway
2016-10-13
Active, closed
14022 ATTUNE Cementless RP Clinical Performance Evaluation
NCT02839850 Osteoarthritis
DePuy Orthopaedics
Not applicable
540
Cork
2016-09-01
Recruiting
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707 Community-acquired Pneumonia, Influenza, COVID-19
DrugsConvalescent plasma·Repagermanium·Telmisartan·Captopril
UMC Utrecht
Phase 3
20,000
Cork, Dublin, Galway, Waterford
2016-04-11
Active, closed
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
NCT02804815 Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer
DrugAspirin
University College, London
Phase 3
11,000
Cork, Dublin, Galway, Limerick, Sligo, Waterford
2015-10
Active, closed
Phase III Radium 223 mCRPC-PEACE III
NCT02194842 Prostate Cancer
DrugsRa223·Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
446
Cork, Dublin
2015-10
Active, closed
PALbociclib CoLlaborative Adjuvant Study
NCT02513394 Breast Cancer
DrugPalbociclib
Alliance Foundation Trials, LLC.
Phase 3
5,796
Cork, Dublin, Limerick, Sligo, Waterford
2015-08
Active, closed
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
NCT02446444 Prostatic Neoplasms
DrugsLhrha·Enzalutamide
University of Sydney
Phase 3
802
Cork, Galway, Dublin
2014-03
Active, closed
TAILORx Tissue Bank
NCT02050750 Breast Cancer
Cancer Trials Ireland
Observational
600
Cork, Donegal, Dublin, Galway, Limerick, Sligo, Waterford
2013-12
Active, closed
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
NCT01957436 Metastatic Prostate Cancer
DrugsZytiga·Abiraterone acetate·Docetaxel
UNICANCER
Phase 3
1,173
Cork, Dublin, Galway
2013-11-13
Recruiting
Breast Cancer Proteomics and Molecular Heterogeneity
NCT01840293 Primary Breast Cancer, Recurrent/Metastatic Breast Cancer
Cancer Trials Ireland
Observational
1,780
Cork, Dublin, Limerick, Waterford
2013-02
Active, closed
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
NCT01272037 Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma
DrugsTamoxifen Citrate·Tamoxifen·Exemestane·Anastrozole
National Cancer Institute (NCI)
Phase 3
5,018
Cork, Dublin, Mount Merrion, Galway, Limerick, Sligo, Waterford, Letterkenny
2011-02-28
Active, closed
Male Breast Cancer: Understanding the Biology for Improved Patient Care
NCT01101425 Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Observational
200
Cork, Dublin, Waterford
2010-12
Active, closed
A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17
NCT00951535 Prostate Cancer
Cancer Trials Ireland
Phase 2
251
Cork, Dublin
2009-07-20
Active, closed
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
NCT00310180 Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
DrugsTamoxifen Citrate·Tamoxifen·Exemestane·Anastrozole
National Cancer Institute (NCI)
Phase 3
10,273
Cork, Dublin, Mount Merrion, Galway, Limerick, Sligo, Waterford, Letterkenny
2006-04-07
Rows per page Showing 1–170 of 170
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Irish investigative site, filtered. Derived from ClinicalTrials.gov, U.S. National Library of Medicine. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-ireland/city/cork

Query this register directly
GET /api/trials?country=ie&status=recruiting&phase=Phase+3&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Ireland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 602 studies in total at the last sync on 06 Oct 2026, 03:15 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 170 of those studies with a site in Cork.

How many clinical trials are recruiting in Cork?

82 of the 170 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:15 UTC sync. A further 5 have not yet opened recruitment, 82 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cork), 170 studies
PhaseStudiesRecruitingShare
Phase 3973957.1%
Not applicable311818.2%
Observational191211.2%
Phase 21247.1%
Phase 2/3552.9%
Phase 1/2331.8%
Phase 1211.2%
Phase 4100.6%

Most active sponsors

Lead sponsors with the most studies (Cork)
Lead sponsorStudiesRecruiting
University College Cork1711
Merck Sharp & Dohme LLC159
Cancer Trials Ireland84
AbbVie71
AstraZeneca73
Bristol-Myers Squibb43
Celgene41
Daiichi Sankyo42
Regeneron Pharmaceuticals41
Stichting Hemato-Oncologie voor Volwassenen Nederland42
Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. For trials across the wider EU, see the EU Clinical Trials Tracker.